2015
DOI: 10.1016/j.healun.2015.01.003
|View full text |Cite
|
Sign up to set email alerts
|

The role of the endothelin-1 pathway as a biomarker for donor lung assessment in clinical ex vivo lung perfusion

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
40
3

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 46 publications
(46 citation statements)
references
References 23 publications
(30 reference statements)
3
40
3
Order By: Relevance
“…This could be further elaborated using a biomarker for lung acceptance such as endothelin 1 (15) and interleukin-1b/tumor necrosis factora (16), which are already being proposed, among others, as promising markers. This could be used to relate the rather subjective CT findings to a quantifiable parameter that might aid in further decision-making.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This could be further elaborated using a biomarker for lung acceptance such as endothelin 1 (15) and interleukin-1b/tumor necrosis factora (16), which are already being proposed, among others, as promising markers. This could be used to relate the rather subjective CT findings to a quantifiable parameter that might aid in further decision-making.…”
Section: Discussionmentioning
confidence: 99%
“…This could be used to relate the rather subjective CT findings to a quantifiable parameter that might aid in further decision-making. This could be further elaborated using a biomarker for lung acceptance such as endothelin 1 (15) and interleukin-1b/tumor necrosis factora (16), which are already being proposed, among others, as promising markers.…”
Section: Discussionmentioning
confidence: 99%
“…There is further data to suggest that EVLP has both the potential for benefit and harm, as seen by an increase in inflammation observed during EVLP . There are also ongoing investigations looking for further prognosticating parameters during EVLP to predict quality post‐transplantation, including biomarkers . The pragmatic concerns with biomarker analysis is often related to the time lag between sampling and test results, which does not allow for real‐time clinical decision making to be impacted by most associative biomarker studies .…”
Section: Discussionmentioning
confidence: 99%
“…The best biomarker to differentiate declined lungs from control lungs was stem cell growth factor‐β (p < 0.001; area under the curve (AUC) = 0.86), whereas the best markers to differentiate PGD grade‐3 from control cases were interleukin‐8 (p < 0.001; AUC = 0.93) and growth‐regulated oncogen‐α (p = 0.001; AUC = 0.89) . A contemporary paper also published by the Toronto group and using the same study design identified big endothelin‐1 as a biomarker of PGD grade‐3 lungs (control group vs. PGD group; p = 0.01; AUC = 0.96) and EVLP‐assessed lungs declined for LTx (control group vs. declined group; p = 0.003; AUC = 0.92) .…”
Section: Evlp: the Futurementioning
confidence: 94%